...
首页> 外文期刊>Biochemistry >Cellular Copper Import by Nanocarrier Systems, Intracellular Availability, and Effects on Amyloid β Peptide Secretion
【24h】

Cellular Copper Import by Nanocarrier Systems, Intracellular Availability, and Effects on Amyloid β Peptide Secretion

机译:纳米载体系统导入细胞铜,细胞内可用性以及对淀粉样β肽分泌的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Studies in animals have reported that normalized or elevated Cu levels can inhibit or even removenAlzheimer’s disease-related pathological plaques and exert a desirable amyloid-modifying effect. We testednengineered nanocarriers composed of diverse core-shell architectures to modulate Cu levels undernphysiological conditions through bypassing the cellular Cu uptake systems. Two different nanocarriernsystems were able to transport Cu across the plasma membrane of yeast or higher eukaryotic cells, CS-NPsn(core-shell nanoparticles) and CMS-NPs (core-multishell nanoparticles). Intracellular Cu levels could benincreased up to 3-fold above normal with a sublethal dose of carriers. Both types of carriers released theirnbound guest molecules into the cytosolic compartment where they were accessible for the Cu-dependentnenzyme SOD1. In particular, CS-NPs reduced Aβ levels and targeted intracellular organelles more efficientlynthan CMS-NPs. Fluorescently labeled CMS-NPs unraveled a cellular uptake mechanism, which depended onnclathrin-mediated endocytosis in an energy-dependentmanner. In contrast, the transport ofCS-NPs wasmostnlikely driven by a concentration gradient. Overall, nanocarriers depending on the nature of the surroundingnshell functioned by mediating import of Cu across cellular membranes, increased levels of bioavailable Cu,nand affected Aβ turnover. Our studies illustrate that Cu-charged nanocarriers can achieve a reasonable metalnion specificity and represent an alternative to metal-complexing agents. The results demonstrate that carriernstrategies have potential for the treatment of metal ion deficiency disorders
机译:动物研究报告称,正常或升高的铜水平可以抑制甚至消除阿尔茨海默氏病相关的病理斑块,并具有理想的淀粉样蛋白修饰作用。我们测试了由多种核-壳结构组成的工程化纳米载体,以通过绕过细胞吸收铜的机制,在生理条件下调节铜水平。两种不同的纳米载体系统能够将Cu跨酵母或高等真核细胞的质膜运输,即CS-NPsn(核-壳纳米颗粒)和CMS-NP(核-多壳纳米颗粒)。在亚致死剂量的载体下,细胞内铜水平可能会比正常水平增加多达三倍。两种类型的载体都将其结合的客体分子释放到胞质区室,在那里铜依赖性酶SOD1可以访问它们。特别地,与CMS-NP相比,CS-NP更有效地降低了Aβ水平并靶向了细胞内细胞器。荧光标记的CMS-NPs揭示了细胞摄取机制,该机制依赖于能量依赖的方式依赖于claclathrin介导的内吞作用。相反,CS-NPs的转运最有可能是由浓度梯度驱动的。总体而言,取决于载体性质的纳米载体通过介导铜跨细胞膜的进口,增加可利用的铜水平,影响Aβ的转化而起作用。我们的研究表明,带铜电荷的纳米载体可以实现合理的金属离子特异性,并且可以替代金属络合剂。结果表明,载体策略具有治疗金属离子缺乏症的潜力

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号